Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|67|1|51-62

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.1, 2015-01, pp. : 51-62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective

By Fleischmann Roy M  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 255-266

Future Medicine

Access to resources Recommend Favorite

Tumour necrosis factor-α, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis

By Fröde Tânia Silvia   Tenconi Patrícia   Debiasi Marilei Reynaud   Medeiros Yara Santos  

Mediators of Inflammation, Vol. 11, Iss. 6, 2002-12 ,pp. : 345-349

Informa Healthcare

Access to resources Recommend Favorite

Necrobiosis lipoidica occurring in a patient with rheumatoid arthritis on concurrent tumor necrosis factor‐α inhibitor therapy

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 11, 2015-11 ,pp. : 1294-1296

John Wiley & Sons Inc

Access to resources Recommend Favorite

Salivary interleukin‐17 and tumor necrosis factor‐α in relation to periodontitis and glycemic status in type 2 diabetes mellitus 2型糖尿病患者唾液中的白细胞介素‐17以及肿瘤坏死因子‐α与牙周炎以及血糖水平相关

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 5, 2015-09 ,pp. : 681-688

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does Combined Clinical and Ultrasound Assessment Allow Selection of Individuals With Rheumatoid Arthritis for Sustained Reduction of Anti–Tumor Necrosis Factor Therapy?

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 6, 2015-05 ,pp. : 746-753

John Wiley & Sons Inc

Access to resources Recommend Favorite